Q1 Improved Trading Performance & FY24 Guidance Maintained
A: 78 Apollo Drive, Rosedale, Auckland 0632, New Zealand
PO Box: 302-533 North Harbour, Auckland 0751, New
Zealand
P: + 64 9 477 4500 E: info@aofrio.com
® is a registered Trademark of AoFrio Ltd.
23 April 2024
Market Announcement
For immediate release
Q1 Improved Trading Performance and FY2024 Guidance Maintained
AoFrio Limited (AOF), is providing an update on trading performance for the three months ended 31 March
2024 (Q1-2024).
• Revenue for Q1-2024 was $16.6m, a 13% increase compared to $14.7m for Q1-2023.
• IoT revenue was $9.9m compared to $9.4m in 2023.
• Revenue from the sale of motor products was $6.7m, compared to $5.3m in 2023.
• Gross Margin was 31.3% (32.3% in Q1-2023), reflecting an increase in sales of motor products.
• Operating Costs for Q1 were $5.1m compared to $5.4m in 2023.
• EBITDA improved by $0.6m to a surplus $0.2m (loss of $0.4m in Q1-2023).
• Cash at 31 March 2024 was $2.1m ($2.9m last year at 31 March) and the Company had borrowed
$3.9m under its $5m trade finance facility ($4.1m last year at 31 March).
At the AoFrio Annual General Meeting held in May 2023, AOF outlined its key strategic initiatives. One of
these was to secure large IoT customers in the USA Market. In Q1-2024 AOF received its first US$1.0
million order for its solution into the Coca-Cola Network in the USA. The food services and food retail
markets are progressing well and AOF expects to launch its first version of the solution in Q4 this year.
It has been an encouraging start to the 2024 year. Q2-2024 is expected to also show robust growth over Q2-
2023.
2024 Outlook
AoFrio is maintaining its 2024 guidance.
Revenue in FY24 is expected in the range $70m to $80m, a 13% increase over FY23 at the midpoint of the
range. AOF’s EBITDA guidance for FY24 is targeting around $2.5m. Macroeconomic conditions may impact
this guidance. AOF continues to manage its investment in growth (mainly additional staff) to align with
trading conditions and expects to be able to continue expanding through internally generated cashflows.
*EBITDA (i.e., Earnings before interest, taxation, depreciation, amortisation, and impairment) is a non-GAAP
earnings figure that equity analysts tend to focus on for comparable company performance analysis. AoFrio
considers it a valuable financial indicator because it avoids the distortions caused by differences in
amortisation and impairment policies. Contact
Ends
AO106
A: 78 Apollo Drive, Rosedale, Auckland 0632, New Zealand
PO Box: 302-533 North Harbour, Auckland 0751, New
Zealand
P: + 64 9 477 4500 E: info@aofrio.com
® is a registered Trademark of AoFrio Ltd.
Contact
Greg Balla Howard Milliner
Chief Executive Officer Chief Financial Officer
Phone + 64 21938601 +64 275870455
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- AFT — AFT Pharmaceuticals Limited: AFT reports record revenue and earnings2024-05-22
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 Results for announcement to the market AFT Pharmaceuticals Limited Reporting Period 12 months to 31 March 2024 Previo…”
- AFT — AFT Pharmaceuticals Limited: AFT to announce full year results on May 23 20242024-05-02
“3 May 2024 AFT Pharmaceuticals to announce full year results on Thursday May 23 2024 AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release its full year FY2024, ended March 31 2024, results on Thursday May 23 2024. The release will b…”
- AFT — AFT Pharmaceuticals Limited: AFT updates operating profit guidance to $23m to $25m2024-02-15
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com 16 February 2024 AFT updates operating profit guidance to $23m to $25m AFT Ph…”